Objectives: The aims of this study were to provide a cost-effective and valuable method for evaluating drug efficacy against Cryptosporidium parvum using a quantitative SYBR Green real-time PCR (qPCR) and to assess the efficacy of adenosine analogues as drug templates.
Introduction
Cryptosporidiosis is a life-threatening disease 1 mainly due to the lack of effective chemotherapy against Cryptosporidium, especially in immunocompromised individuals such as those with AIDS, and those undergoing transplantation or anticancer chemotherapy. To overcome the difficulties involved in the treatment of human cryptosporidiosis, drug-screening trials using various reagents have been conducted. 2 -4 Even though quantitative PCR (qPCR) assays, especially reverse transcriptase qPCRs, 2, 3 have been considered to be appropriate for quantifying living parasites, mRNA quantification may be affected under certain cellular conditions because of changes in expression as observed through various microarray data. Therefore, an accurate, reproducible, alternative method is required.
Recently S-adenosyl-L-homocysteine hydrolase (SAHH) has been recognized as an attractive target for antiparasitic and antiviral agents. 3, 5, 6 SAHH catalyses the reversible hydrolysis of S-adenosyl-L-homocysteine (SAH) to adenosine and homocysteine. SAHH thereby plays an important role in regulating the cellular levels of SAH, which is a potent feedback inhibitor of SAH-dependent methylation reactions. Moreover, SAHH is a conserved enzyme of sulphur-containing amino acid metabolism in Cryptosporidium parvum; 7 this enzyme is a crucial metabolic enzyme and may be an attractive target for novel anticryptosporidial agents.
In this study, we developed a novel method for assessing the efficacy of drugs against C. parvum using qPCR and assessed the anticryptosporidial efficacy and enzymatic inhibitory activity of adenosine analogues.
Materials and methods
In vitro cell culture for C. parvum
For the collection of oocysts and the in vitro development of C. parvum, a previously described procedure 8 was used with some modifications. In brief, oocysts of C. parvum HNJ-1 strain 9 were stored at 48C in PBS containing penicillin and streptomycin (100 U/mL each), and were used for infection within 4 months after purification. Human ileocaecal adenocarcinoma (HCT-8) cells were cultivated in 24-well plates in RPMI Medium 1640 supplemented with 10% fetal bovine serum and 4 mM L-glutamine (GlutaMAX TM -1) (GIBCO, Grand Island, NY, USA). After treatment with 50 mM hydrochloric acid and washing with PBS, 1.6×10 5 oocysts were inoculated onto cell monolayers in medium supplemented with 0.1% bile; the cells were allowed to incubate for 2 h at 378C, and the conditions induced approximately 20% excystation (data not shown). Cell monolayers were washed twice to remove unexcysted oocysts. The medium was replaced with fresh medium with or without the tested substrates and incubated for 24 h in order to evaluate drug efficacy during the initial C. parvum growth before initiating the reinvasion of merozoites. As a result of the protocol, the correlation between the quantity of genomic DNA and the number of inoculated oocysts was confirmed (data not shown).
DNA extraction
The cell monolayers were washed twice, detached using trypsin-EDTA (GIBCO), and collected in microcentrifuge tubes by centrifugation (5 min at 5200 g). After 3 cycles of freezing and thawing, 10 6 copies of a constructed plasmid harbouring the Cyclospora cayetanensis 18S rRNA (Cc18SrRNA) gene were added to each collected cell sample to normalize the DNA extraction efficiency. Genomic DNA was purified using the PrepMan w Ultra Sample Preparation Reagent (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.
qPCR assay
The primer targets were the C. parvum methionine adenosyltransferase (CpMAT; a single-copy gene), human b-actin (HsACTB) and Cc18SrRNA, and these were performed as three independent qPCRs. Standard plasmids containing CpMAT (Sequence ID in CryptoDB: CM000435; 624788-625264 bp), HsACTB (accession number: AY582799; 3274-3380 bp), and Cc18SrRNA (AF111183; 439-1074 bp) were constructed to make a standard curve. Each gene was subcloned into a pBluescript II SK(+) vector (Stratagene, CA, USA) digested by EcoRV (TaKaRa Bio Inc., Shiga, Japan). Escherichia coli DH5a cells containing each plasmid were harvested in Luria-Bertani (LB) broth with 100 mg/mL ampicillin at 378C. The plasmids were purified using a QIAGEN Plasmid Midi Kit (QIAGEN Sciences, MD, USA) and quantified using PicoGreen w dsDNA quantitation reagent (Molecular Probes Inc., Eugene, OR, USA).
Each 20 mL reaction mixture contained 10 mL of 2× SYBR w Premix Ex Taq TM (TaKaRa), 0.4 mL of 50× ROX Reference Dye, 0.4 mL of 10 mM forward and reverse primer mix and 9.2 mL of DNA of infected cells or 1 mL of each standard plasmid. The reaction mixtures were initially heated at 958C for 10 min and then subjected to 40 thermal cycles (958C for 15 s and 608C for 1 min) with an ABI PRISM 7700 Sequence Detection System (Applied Biosystems).
Tested compounds
Two adenosine analogues, neplanocin A (NPA) and 2-fluoroadenosine (2FA; Sigma-Aldrich, St Louis, MO, USA), were dissolved in 50% DMSO to prepare stock solutions.
CpSAHH-pCold I construction and recombinant CpSAHH expression
The subcloned CpSAHH gene (AY161083) from the pBluescript II SK(+) vector was inserted into pCold I DNA digested by XhoI and EcoRI (TaKaRa). E. coli BL21 cells transformed by the constructed plasmid were harvested in LB broth with 100 mg/mL ampicillin at 378C until the OD 600 was between 0.4 and 0.5. His-Tag fusion CpSAHH protein was expressed by induction with 0.5 mM IPTG at 158C for 24 h and purified by metal affinity chromatography using His . Bind w Kits (Novagen, Merck KGaA, Darmstadt, Germany).
Enzyme assay and kinetic analyses
The activity of recombinant CpSAHH was assayed on the basis of a previous report. 10 The standard reaction mixture contained SAH (6.25-200 mM) and 100 mM 5,5
′ -dithiobis-2-nitrobenzoate (Sigma-Aldrich) in 100 mM phosphate buffer (pH 7.2). The reaction was initiated by the addition of CpSAHH, and the increase in product was monitored spectrophotometrically at 414 nm (Labsystems iEMS Reader MF; Labsystems, Helsinki, Finland) at 378C for 1 min. One unit was defined as the amount of enzyme that produces 1 mmol of product in 1 min. An inhibition assay was carried out by pre-incubating the standard mixture with 2FA or NPA at 378C for 10 min and was initiated by the addition of CpSAHH. Kinetic parameters were obtained using the MichaelisMenten equation and Lineweaver -Burk plots (SigmaPlot; Systat Software Inc., San Jose, CA, USA).
Results

Anticryptosporidial efficacy of the adenosine analogues
A qPCR assay was employed to evaluate the effect of the two adenosine analogues (Figure 1 ) on the growth of C. parvum in vitro. NPA inhibited the growth of C. parvum in a dose-dependent manner; the 50% effective concentration (EC 50 ) was 139 mM. No cytotoxicity was observed using NPA up to 200 mM. 2FA appeared to have a dose-dependent inhibitory effect on C. parvum growth (EC 50 ¼ 0.842 mM) (Figure 1 ). However, 2FA was also cytotoxic to human cells; some cells floated up in the culture medium containing high concentrations of 2FA, and the 50% inhibitory concentration (IC 50 ) to host cells was 1.18 mM. Therefore, the apparent high efficacy of 2FA was non-specific due to the suppression of host cell growth.
Kinetic properties and inhibition analyses of CpSAHH
The activity of recombinant CpSAHH was measured in the hydrolytic direction, and kinetic data were obtained under standard conditions. The Lineweaver -Burk plot indicated that K m and V max were 49.8 mM and 0.803 mmol/min/mg, respectively. NPA exhibited competitive inhibition (Figure 2) , and the K i was 0.395 mM, meanwhile, 2FA (up to 100 mM) did not inhibit CpSAHH activity (data not shown).
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Discussion
An unavoidable difficulty in the in vitro drug assessment of Cryptosporidium is that proliferation is incomplete in the culture system; 1 sporozoite divides into 8 merozoites in a host epithelial cell after 24 h of invasion, and reinvasion of those merozoites into surrounding cells appears to be negligible. In fact, our preliminary evaluation indicated that the DNA quantity of C. parvum increased approximately 8-fold (8.97+1.95 times) during the initial 24 h post infection (data not shown). Therefore, precise quantification is necessary. In this study, an exogenous control was employed to normalize the DNA extraction efficiency and qPCR assay. This quantitative system revealed that the EC 50 of 2FA for C. parvum (0.842 mM) was similar to its IC 50 for cells (1.18 mM), making it a non-specific inhibitor. Therefore, the efficacy of 2FA against C. parvum was considered to be due to the suppression of host cell growth. Moreover, compared with the qPCR system using TaqMan probes, 4 the SYBR Green system is low cost. Thus, this novel, precise, and cost-effective method of drug screening could provide various opportunities for assessing drug efficacy against C. parvum. Although there are no data regarding intraspecies variations of drug susceptibility among the C. parvum population in endemic areas, our method can be used for drug susceptibility or resistance evaluations at clinical sites.
Anticryptosporidial efficacy of NPA was marginal (EC 50 ¼ 139 mM), indicating that C. parvum is relatively resistant to adenosine analogues in contrast to Plasmodium falciparum (EC 50 ¼ 0.20 mM) 5 and HIV (EC 50 ¼ 0.001-0.1 mM), 6 however, only NPA competitively inhibited the activity of recombinant CpSAHH. This fact indicates that SAHH is also a critical metabolic step in C. parvum and may be a target of drug development.
Although further studies including in vivo evaluations are necessary to provide novel chemotherapy, an accurate and costeffective SYBR Green-based qPCR assessment procedure was established for evaluating drugs against C. parvum in vitro. Regarding the drug screening of adenosine analogues, this method revealed the cytotoxicity of 2FA and moderate anticryptosporidial efficacy of NPA. This novel method could be used in a wide variety of clinical and research-oriented applications of Cryptosporidium analysis. 
